1Q EARNINGS: AbbVie buoyed by Humira, touts hepatitis C program
This article was originally published in Scrip
A 17.5% jump in Humira (adalimumab) sales to $2.6bn in the first quarter kept AbbVie's net product sales in positive territory as therapies for controlling cholesterol plunged due to generic competition, putting greater emphasis on the company's future in hepatitis C.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.